Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
March 15, 2019
Quantitative pharmacology encompasses the many strategic advantages of using complex mathematical models to understand...
Read article
January 30, 2019
Career Perspectives: Interview with Tina Checchio, Associate Director, Quantitative Pharmacology & Pharmacometrics
QPP remains at the heart of model based drug development. Short for Quantitative Pharmacology & Pharmacometrics, it...
Read article
January 10, 2019
Podcast: Overcoming Phase 1 Development Challenges
Nand Kishore Rawat is a Director and Head, Early Phase Biostatistics based in the King of Prussia, PA Cytel office. We...
Read article
August 8, 2018
How can a strategic pharmacometrics consultant add value to your team?
We have written on the blog in the past about the value that a statistical consultant can bring to your team, and to...
Read article
May 31, 2018
5 Reasons to Integrate MBMA Into Your Clinical Development Strategy
By Esha Senchaudhuri An important trend in clinical development involves integrating strategic pharmacometric analysis...
Read article
January 26, 2018
6 Innovative Trial Design Videos
The Cytel YouTube Channel hosts a wealth of video presentations from Cytel experts as well as external industry and...
Read article
November 6, 2017
Asking the Right Questions of Your Data: Experiences in Model Informed Drug Development
At the Chief Medical Officer Summit earlier this year, Cytel's Director of Quantitative Pharmacology and...
Read article
August 10, 2017
4 Questions to Explore in Model-Informed Drug Development (Infographic)
Model-informed drug development has been defined by Richard Lalonde ( Lalonde, 2007) (1) as “Development and...
Read article
June 12, 2017
Predictions of Pharmacodynamic Responses in Ulcerative Colitis Patient
The Population Approach Group in Europe (PAGE) represents a community with a shared interest in data analysis using the...
Read article
January 5, 2017
SAS and NONMEM - a marriage made in heaven?
Nonlinear Mixed Effects Modeling (NONMEM) is a type of population pharmacokinetics/pharmacodynamics (popPK/PD) analysis...
Read article
November 18, 2016
Case Study: Dose-response modeling informs Phase 2 ulcerative colitis study design
Challenge Our client had the following key questions which they wanted our pharmacometrics group to address for an...
Read article
November 1, 2016
Pharmacometrics tools of the trade: 4 factors to consider
Unlike statistics which has been around in some form for hundreds of years, pharmacometrics is, by comparison, a...
Read article
September 20, 2016
An efficient tool for model based meta-analysis
Drug development is an expensive and risky business. To maximize a compound’s ultimate chances of commercial as well as...
Read article
September 13, 2016
Case Study:Exposure Response Modeling in Hematology
Exposure-response data gained from clinical studies can provide a basis for model-based analysis and simulation,...
Read article
May 17, 2016
Scrambled Data – A Population PK/PD Programming Solution
Cytel participated at PharmaSUG 2016 in Denver recently. A key event on the statistical programming global calendar,...
Read article
November 3, 2015
Pharmacometrics for Biomarker Driven Clinical Strategy
QPP (sometimes called QP2) remains at the heart of model based drug development. Short for Quantitative Pharmacology &...
Read article
October 1, 2015
It’s Time to Bridge the Gap Between Pharmacometrics and Biostats
This week marks the sixth annual American Conference on Pharmacometrics, held this year in Crystal City, VA. Situated...
Read article